Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rectal bacteriotherapy or faecal microbiota transplantation versus oral vancomycin for recurrent Clostridium difficile infection
2015-003062-82Phase 3Terminated
- Sponsor
- Zealand University Hospital
- Start
- Nov 2016
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of vancomycin and allogeneic fecal microbiota in Clostridioides difficile infection (CDI) (3 arms), sponsored by Zealand University Hospital. Primary endpoint: Clinical cure at 90 days. Started Nov 2016; status: terminated.
02
Drugs
vancomycinallogeneic fecal microbiota
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on 2015-003062-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003062-82.